Market Performance - The US stock market closed higher, with the S&P 500 index reaching a new high. The Dow Jones increased by 0.16%, the S&P 500 rose by 0.46%, and the Nasdaq gained 0.57% [1] - Major tech stocks performed well, with Nvidia up 3.01%, Broadcom up 2.30%, Amazon up 1.62%, and Google A shares up 1.48% [1] Commodity Prices - Spot silver continued its strong performance, reaching a new historical high, increasing by 3% to $71.06 per ounce, with a year-to-date increase of 145% [2] - Spot gold rose by 0.8%, reaching $4478.52 per ounce, hitting a record high during the trading session [3] - International oil prices slightly increased, with New York crude oil futures closing at $58.38 per barrel [4] Regulatory Developments - The National Development and Reform Commission, Ministry of Education, and Ministry of Finance in China issued a notice to improve kindergarten fee policies, emphasizing the need for financial transparency and regulation of fees [4] - A new regulation on food safety in live-streaming e-commerce is set to be published, outlining responsibilities for platform operators and marketing personnel [5][6] Corporate News - Sunac China announced that approximately $9.6 billion of its existing offshore debt has been fully released and exempted [6] - Haibo Technology plans to invest 2 billion yuan to build a smart green energy storage factory [6] - Bethel plans to issue H-shares and list on the Hong Kong Stock Exchange [6] - Ningbo Port intends to acquire 100% equity of Zhoushan Port Comprehensive Bonded Zone for 706 million yuan [6]

证券代码：688366 证券简称：昊海生科公告编号：2025-052 上海昊海生物科技股份有限公司 关于公司控股股东、实际控制人之一因非本公司事项 收到《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）控股股东、实际控制人之一蒋伟先生此前因非本公 司事项，收到中国证券监督管理委员会（以下简称"中国证监会"）出具的《行政处罚事先告知书》（处 罚字[2025]67号）。具体内容详见公司2025年9月17日于上海证券交易所网站（www.sse.com.cn）披露的 《上海昊海生物科技股份有限公司关于公司控股股东、实际控制人之一因非本公司事项收到〈行政处罚 事先告知书〉的公告》（公告编号：2025-042）。 近日，公司收到蒋伟先生告知，获悉其因前述事项，收到了中国证监会出具的《行政处罚决定书》 （[2025]151号）。行政处罚决定书的主要内容为：因蒋伟先生内幕交易、建议他人买卖证券行为，中 国证监会决定没收其违法所得4,709,741.41元 ...

Core Viewpoint - The announcement from Haohai Biological Technology indicates that the company's actual controller, Jiang Wei, has been penalized for insider trading, with a total fine and confiscation amounting to 19.34 million yuan. The company asserts that this matter is unrelated to its operations and will not significantly impact its business or financials [2][3]. Group 1: Regulatory Actions - Jiang Wei received an administrative penalty from the China Securities Regulatory Commission (CSRC) for insider trading, with a confiscation of illegal gains amounting to 4.71 million yuan and a fine of 14.63 million yuan, totaling 19.34 million yuan [2][3]. - The penalty is directed at Jiang Wei personally, and the company emphasizes that it is not involved in the matter, as Jiang does not participate in daily management [2][3]. Group 2: Company Background - Haohai Biological Technology was established in 2007 and listed on the Hong Kong Stock Exchange in 2015, later becoming the first company to be listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board in October 2019 [2][3]. - The company primarily engages in the production and sales of biopharmaceuticals, including medical sodium hyaluronate gel, epidermal growth factor, chitosan, collagen, artificial crystals, and ophthalmic implants [3]. Group 3: Financial Performance - For the first three quarters of 2025, Haohai Biological Technology reported total revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down over 10% [4]. - The net cash flow from operating activities for the same period was 377 million yuan, reflecting a decline of 12.45% year-on-year, attributed to insufficient domestic consumer demand, price competition, and tax rate adjustments [4]. Group 4: Capital Operations - Despite the investigation of its actual controller, Haohai Biological Technology continued its capital operations, announcing on November 9 that it plans to acquire the remaining 20% stake in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for 74 million yuan, which would result in the company holding 100% of the target company's equity [5].

Shareholder Reductions - Zhang Fan from 壹网壹创 plans to reduce his holdings by no more than 2.5% [1] - Yan Jun, honorary chairman and chief scientist of 航宇微, intends to reduce his holdings by no more than 1.66% [1] - 长安信托·中保投1号信托, a shareholder of 紫光股份, plans to reduce its holdings by no more than 1% [1] - Jiang Shuguang, deputy general manager of 崇达技术, plans to reduce his holdings by no more than 200,000 shares [1] - 热景生物 intends to sell back repurchased shares not exceeding 1.8542 million shares [1] - Yuan Meihe, a shareholder of 欧科亿, plans to reduce his holdings by no more than 1.89% [1] - Zhu Fengxue and his concerted actions from 中曼石油 will collectively reduce their holdings by 0.35% [1] - Tokyo Guorui, a shareholder of 燕东微, has already reduced its holdings by 0.88% [1] - Huaguang New Materials' shareholder, Huan Guang Investment, has cumulatively reduced its holdings by 1.60% [1] - Jiayuan Group has reduced its holdings in 吉祥航空 by 8.6065 million shares [1] - Longgao Electric New from 富特科技 has cumulatively reduced its holdings by 1.00% [1] - Actual controller Shi Huiqing from 可川科技 has reduced his holdings by 1.05% [1] - Lu Xinchun, a shareholder of 华海清科, has reduced his holdings by 3.3156 million shares [1] Other Corporate Actions - 建设机械 has terminated the issuance of shares to specific objects [1] - 蒋伟, the controlling shareholder of 吴海生科, has been fined 14.6292 million yuan by the China Securities Regulatory Commission [1]

Group 1 - The actual controller of Haohai Biological Technology, Jiang Wei, was penalized approximately 19.34 million yuan for insider trading and suggesting others to trade securities, with 4.71 million yuan confiscated as illegal gains and a fine of 14.63 million yuan imposed by the China Securities Regulatory Commission [2][4]. - Haohai Biological Technology stated that the penalty is directed at Jiang Wei personally and is unrelated to the company, asserting that it will not significantly impact the company's daily operations, business, or finances [4][5]. - As of the end of the third quarter, Jiang Wei is the largest shareholder of Haohai Biological Technology, holding 66.528 million shares, which accounts for 28.6% of the total shares [4][5]. Group 2 - Haohai Biological Technology plans to enter the biological amniotic membrane sector by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan [7]. - Ruiji Biological specializes in the research, production, and sales of biological amniotic membranes, which are used in orthopedic and ophthalmic fields [7]. - The investment aims to enhance Haohai's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [7]. Group 3 - Ruiji Biological's financial performance is concerning, with a projected net profit of -12.74 million yuan for 2024 and a loss of 11.93 million yuan for the first three quarters of 2025 [8][9]. - The transaction does not include performance commitments or profit guarantees, indicating potential risks for Haohai if Ruiji's performance declines [9]. - As of December 23, Haohai Biological Technology's stock price was 44.25 yuan per share, with a total market capitalization of 10.292 billion yuan [10].

（来源：财闻） "八连板"胜通能源称，如未来公司股票价格进一步上涨，公司可能向深圳证券交易所申请停牌核查。 项目投资 九丰能源（605090.SH）：公司特种气体业务的战略定位为航空航天特气，并锚定商业航天特燃特气需 求领域。除海南商业航天发射场特燃特气配套项目外，公司积极拓展山东海阳东方航天港、甘肃酒泉卫 星发射中心等其他商业航天发射基地的特燃特气合作项目，并全部进入实施阶段。 截至目前，公司多次与上海航天设备制造总厂有限公司（隶属中国航天科技集团有限公司第八研究院） 签署相关协议；公司多次与中国航天科技集团商业火箭有限公司（隶属中国航天科技集团有限公司）签 署相关协议；公司与中国长征火箭有限公司（隶属中国航天科技集团有限公司第一研究院）签署相关协 议，与北京天兵科技有限公司签署相关协议；公司已中标上海空间推进研究所（隶属中国航天科技集团 有限公司第六研究院）三年期氦气、氮气等产品综合保障服务项目。 重大合同 宁波华翔（002048.SZ）：公司下属子公司宁波华翔启源科技有限公司与国内某头部机器人关节厂商签 订了《机器人关节委托生产合同》，将在未来两年内为其生产制造部分机器人关节产品。该合作将有利 于华翔启 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於公司控股股東、實際控制人之一因非本公司事項收到<行政處罰決定書>的公 告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年12月23日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 一 ...

Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, has been penalized approximately 19.34 million yuan for insider trading and related activities, which includes the confiscation of illegal gains and fines imposed by the China Securities Regulatory Commission [1][2]. Group 1: Penalty Details - Jiang Wei was fined 1.463 million yuan and had illegal gains of 471 million yuan confiscated by the China Securities Regulatory Commission [1][2]. - The penalty is directed at Jiang Wei personally and is stated to have no significant impact on the company's daily operations or financial status [4]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei holds 66.528 million shares, representing 28.6% of Haohai Biological Technology's total shares [4]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [5]. Group 3: Business Developments - Haohai Biological Technology plans to invest 38.3515 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [6]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [6]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.7415 million yuan for 2024, with a loss of 11.9327 million yuan in the first nine months of 2025 [7][8]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological Technology if Ruiji's performance declines [8].

智通财经APP讯，昊海生科(688366.SH)发布公告，公司控股股东、实际控制人之一蒋伟因内幕交易、 建议他人买卖证券行为，收到中国证监会出具的《行政处罚决定书》，被没收违法所得471万元，并处 以1462.92万元罚款。该处罚决定书所涉主体为蒋伟个人，涉及的事项与公司无关，不会对公司日常经 营、业务及财务造成重大影响。 ...

昊海生科2025年第三季度报告显示，蒋伟系公司第一大股东，直接持股数量为6652.8万股，持股比例为 28.6%；公司第二大股东为游捷，直接持股数量为4032万股，持股比例为17.34%。蒋伟和游捷为夫妻关 系，是公司控股股东、实际控制人。 昊海生科彼时表示，本次事项系对蒋伟个人的调查，其不参与公司日常经营管理，该事项不会对公司日 常经营活动产生重大影响。立案调查期间，蒋伟将积极配合中国证监会开展调查工作。 之后，昊海生科又于2025 年9 月17日公告，蒋伟于近日收到中国证监会出具的《行政处罚事先告知 书》。 昊海生科是一家从事医疗器械和药品研发、生产和销售业务的科技创新型企业，致力于通过技术创新及 转化、国内外资源整合及规模化生产，为市场提供创新医疗产品，逐步实现相关医药产品的进口替代， 成为生物医用材料领域的领军企业。 昊海生科(688366)12月23日晚公告，近日，公司收到控股股东、实际控制人之一蒋伟告知，获悉其收到 了中国证监会出具的《行政处罚决定书》（[2025]151 号）。行政处罚决定书的主要内容为：因蒋伟内 幕交易、建议他人买卖证券行为，中国证监会决定没收其违法所得470.97万 元，并对 ...